Key Takeaways:

  • Cleveland Clinic study of over 10,000 cancer patients found GLP-1 drugs reduced metastatic progression by up to 45%
  • Breast cancer patients saw the strongest protection, with progression risk dropping from 20% to 10%
  • Results will be presented at ASCO 2025 meeting, adding to growing evidence of GLP-1 benefits beyond weight loss

Landmark Study Shows GLP-1s May Prevent Cancer Spread

GLP-1 drugs like semaglutide (Wegovy) and tirzepatide (Zepbound) may help prevent certain cancers from progressing to advanced stages, according to groundbreaking research from the Cleveland Clinic that will be presented at the American Society of Clinical Oncology's annual meeting.

The study examined over 10,000 people who had been diagnosed with stage 1, 2, or 3 cancer and started taking a GLP-1 drug after their cancer diagnosis. The results were particularly striking for breast cancer, where the risk of progression was reduced by 45%.

For breast cancer patients, 20% of those taking DPP-4 inhibitor drugs (the comparison group) saw their cancer progress, compared to only 10% of GLP-1 patients. In colorectal cancer, progression rates were 22% versus 13%, and in liver cancer patients, 28% versus 19%.

Why This Research Matters for Cancer Treatment

Dr. Mark David Orland from Cleveland Clinic's Taussig Cancer Institute, who led the study, said the findings provide "early evidence that future studies are worth pursuing". The researchers used data from TriNetX, a global health research network with information from over 150 million patients, focusing on seven malignancies including breast, colorectal, liver, lung, pancreatic, prostate, and kidney cancers.

What makes this study particularly compelling is the mechanism behind the protection. The association of high GLP-1 receptor levels with better survival suggests that GLP-1's actions could be protective in these cancers, and researchers found a correlation between receptor expression and overall survival.

The connection between diabetes and cancer risk adds another layer of significance to these findings. About 29 to 40 million people in the United States have diabetes, which makes them more susceptible to some cancers due to metabolic dysfunction that creates an environment where cancer can grow, including high levels of insulin and sugar in the blood as well as chronic inflammation.

Growing Evidence of Anti-Cancer Effects

The list of health benefits tied to diabetes and weight loss drugs has been growing — approvals have been expanded to reduce risk of heart disease (Wegovy), prevent worsening kidney disease (Ozempic) and treat obstructive sleep apnea (Zepbound) — and this latest research adds to a growing number of early studies showing that GLP-1s could have anti-cancer effects.

Studies being presented at ASCO 2025 will highlight how GLP-1s could reshape oncology care, with research linking the drugs to lower cancer incidence and better outcomes across several tumor types, as leaders examine what the drugs could mean for cancer risk and outcomes.

As one researcher noted, "GLP-1 receptor agonists have never been glucose-lowering drugs alone. Their anti-inflammatory and immune-modulatory properties have long suggested broader effects".

This research builds on previous studies that have suggested connections between GLP-1 medications and reduced cancer risk. The mechanisms appear to involve multiple pathways, including improved insulin sensitivity, reduced chronic inflammation, and direct effects on cancer cell growth and survival.

Important Limitations and Next Steps

While these results are promising, researchers emphasize important caveats. Even if the benefits are established, GLP-1 drugs are not likely to be a first-line treatment for any cancer, and the most important takeaway is that the drugs appear to be safe to use for diabetes or weight loss in people undergoing cancer treatment, though it's still too soon to recommend GLP-1s for any type of cancer therapy.

GLP-1 drugs are not approved for cancer prevention and are not meant to be used for the purpose of helping reduce cancer risk alone.

Planned next steps include mechanistic studies to understand how GLP-1 receptor agonists may be modulating cancer progression, as well as randomized controlled trials to establish a prospective, causal relationship between GLP-1 use and cancer outcomes.

The research team acknowledges that this was an observational study, which means it can show associations but cannot prove causation. Large-scale clinical trials will be needed to confirm whether GLP-1 drugs directly prevent cancer progression or whether the observed benefits are due to other factors.

What This Means for You

If you're currently taking or considering GLP-1 medications for weight loss or diabetes, this research adds another potential benefit to an already impressive list. While you shouldn't start these medications for cancer prevention alone, the growing body of evidence suggests these drugs may offer broader health protection than initially understood.

If you have a history of cancer or are at higher risk, this research reinforces that GLP-1 medications appear safe during cancer treatment and may even provide additional protection. However, any treatment decisions should always be made in consultation with your healthcare team, including your oncologist if you have a cancer history.

For those exploring treatment options, understanding both the potential benefits and costs is important. You can explore affordable GLP-1 treatment options to find providers in your area who can help you determine if these medications are right for your individual health situation.

The key takeaway is that GLP-1 medications continue to show promise beyond their original intended uses. Whether you're managing diabetes, working on weight loss, or dealing with other health conditions, these drugs appear to offer multiple protective benefits that extend far beyond blood sugar control.